Toronto · Independent Shariah screening · Screened October 1, 2026

TSX Shariah screener · October 2026

MediPharm Labs Corp.

LABS · TSX · Healthcare

FAIL

Is MediPharm Labs Corp. (LABS) Halal?

Debt ÷ market cap 0% / 33%

MediPharm Labs Corp. · TSX: LABS · Healthcare

Price chart by TradingView · Market data may be delayed · Shown for information only — not investment advice.

The short answer

MediPharm Labs Corp. (TSX: LABS) is a FAIL in our October 2026 screen. The business gate fails: it is a pharmaceutical-grade cannabis company and about 15% of Q2 2026 revenue (C$1.5M of C$10.0M) came from Canadian adult-use (recreational) cannabis, above the ~5% de-minimis screen. The debt and income gates are moot: the company is virtually debt free with C$9.9M cash.

Gate 1 — Business activity: FAIL

MediPharm Labs is a pharmaceutical company specialized in precision-based cannabinoids: GMP-certified extraction, purified concentrates and APIs, and derivative products (Barrie, Ontario), plus Beacon Medical subsidiaries in Germany and Australia and Harvest Medicine clinics. Q2 2026 net revenue was C$10.0M (+11% quarter over quarter), split approximately 58% international medical cannabis (C$5.8M), 23% Canadian medical (C$2.3M) and ~15% Canadian adult-use + wellness (C$1.5M); the company says over 80% of revenue comes from regulated medical channels. Adult-use cannabis is recreational cannabis: ~15% of revenue is materially above a ~5% de-minimis screen, and cannabis — across medical and adult-use channels — is the company's core business, not a side line. Facts only.

Gate 2 — Debt and cash: PASS (moot)

The Q2 2026 release describes the company as virtually debt free, with C$9.9M cash and outright ownership of two production facilities appraised at over C$15M. Debt is therefore approximately 0% of the ~C$29.9M market cap (C$0.07). This gate is moot: the screen already fails on the business gate. Facts only.

Gate 3 — Non-compliant income: Not disclosed (moot)

Interest income is not separately disclosed in the Q2 2026 materials reviewed. This gate is moot: the screen already fails on the business gate. Facts only.

BDS screen

Whether this company appears on boycott, divestment and sanctions (BDS) lists. Informational only — it does not change the Shariah screening result above, and it is not a religious ruling.

No BDS listing found on the BDS movement's published boycott, divestment, or pressure lists (checked October 2026).

Moral screen

Beyond the Shariah financial gates, this checks the company’s documented business ties to the Israeli and US militaries, and to weapons manufacturing. Every finding is factual and sourced. A row with no finding means none surfaced in our review — not proof of none.

Israeli military business
No findings published.
US military business
No findings published.
Weapons manufacturing & arms trade
No findings published.

Key figures used

Halal alternatives in this sector

LABS did not pass the screen. These companies in the same sector passed:

Frequently asked questions

Is MediPharm Labs (LABS) halal?

Our October 2026 screen gives MediPharm Labs (LABS) a FAIL. About 15% of its Q2 2026 revenue came from Canadian adult-use (recreational) cannabis, above the ~5% de-minimis screen, and cannabis is its core business across medical and adult-use channels.

Why did MediPharm Labs fail the business gate?

MediPharm is a pharmaceutical-grade cannabis company: GMP-certified extraction, purified concentrates, APIs and derivative products. In Q2 2026, C$1.5M of C$10.0M revenue (~15%) came from Canadian adult-use + wellness, i.e. recreational cannabis. That exceeds the ~5% de-minimis screen applied to non-compliant revenue.

Does MediPharm's medical cannabis business make it halal?

No, not under this screen. Over 80% of revenue comes from regulated medical channels, but ~15% is recreational (adult-use) cannabis, which exceeds the ~5% de-minimis screen, and cannabis is the company's core business. Interpretations differ among scholars; this page reports facts only.

What about MediPharm's debt and interest income?

Both are moot for the overall result. The company is virtually debt free with C$9.9M cash at June 30, 2026, so the debt gate would pass; interest income is not separately disclosed in the Q2 2026 materials. The FAIL comes from the business gate alone.

Where can I find more healthcare stock screeners?

See our full list of stock screeners at halal-stock-verdicts.html, which covers every company screened so far.

Sources

Screened 2026-10-01 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.